GlassScriptPhysician profile
Muhammad Yasir
NPI 1164943882
$5,528.38
in general payments reported to CMS, 2019-2025
25 companies · $2,773 in 2025
The $2,773 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $614 · 2023: $625 · 2024: $1,329 · 2025: $2,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,009 · Travel and Lodging: $638 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,009.04 |
| Travel and Lodging | $638.42 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,189.11 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $1,033.56 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $880.66 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $393.77 | 2022-2025 | |
| Olympus Corporation of The Americas | $362.97 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $247.08 | 2021-2025 | Dupixent |
| Verona Pharma, INC. | $176.96 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $146.61 | 2022-2023 | |
| Amgen INC. | $134.89 | 2024-2025 | Tezspire |
| United Therapeutics Corporation | $134.83 | 2024-2025 | Tyvaso, Tyvaso |
| Kite Pharma, INC. | $114.37 | 2025 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.02 | 2024-2025 | Ofev |
| Axsome Therapeutics, INC. | $103.41 | 2024-2025 | Sunosi |
| Pulmonx Corporation | $103.11 | 2021-2022 | |
| Viatris Specialty LLC | $76.46 | 2025 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $65.01 | 2025 | Zepbound |
| Lexicon Pharmaceuticals, INC. | $38.16 | 2024 | |
| Insmed, INC. | $37.97 | 2021-2025 | Brinsupri |
| Actelion Pharmaceuticals US, INC. | $35.29 | 2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $34.79 | 2024 | |
| Genentech USA, INC. | $30.89 | 2025 | Xolair |
| Mylan Specialty L.P. | $25.40 | 2024 | Yupelri |
| Grifols USA, LLC | $23.83 | 2025 | Prolastin-C Liquid |
| Electromed, INC. | $14.59 | 2024 | Smartvest |
| Breas Medical, INC. | $12.64 | 2025 | Vivo 1/2, Vivo 45 Ls |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Yasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.